Company intelligence / Profile preview

Xalud Therapeutics

New York City, New York, United Statesxaludthera.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Xalud has completed a Phase 2b trial for XT-150 in osteoarthritis of the knee and has an ongoing Phase 1/2a trial in facet joint syndrome. The company has also conducted preclinical studies in ALS, MS, neuropathic pain, and uveitis. In December 2021, XT-150 received FDA Fast Track designation for the treatment of pain associated with osteoarthritis of the knee.

Therapeutic areas: DermatologyRheumatologyOphthalmologyNeurology
Modalities: Non-viral gene therapyplasmid DNA (pDNA) gene therapy
Industry: Biotech

Drug pipeline

2 assets

XT-150

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Xalud Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xalud Therapeutics.

Explore the full profile